MYCN and neuroblastoma: A recent CRISPR/Cas9 screen performed in a panel of neuroblastoma cell lines has led to the identification of EZH2 as a molecular driver of the MYCN-amplified neuroblastomas, paving the way for similar studies in the future [84], importantly, in 2D cell lines, potential chemotherapy [85,86,87,88,89], radiation [90], and immunotherapy [91,92,93,94] screening.